Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

Argenx falls as Sjögren’s setback offsets celiac drug progress

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Sources: endpoints.news · statnews.com · biopharmadive.com

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at biopharmadive.com →

Report a problem with this story

More in Health & Medicine

More from Thursday 8 October →